FDA Steps Into Makena Pricing Dispute In The Name Of "Access"
Executive Summary
FDA is citing patient access as the reason behind its unusual decision to insert itself in the middle of a pricing debate involving KV Pharmaceuticals’ pre-term delivery drug Makena.